Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine + mitoxantrone liposome vs intensive chemotherapy in newly diagnosed intermediate- to high-risk fit AML
ChiCTR2500109764Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of venetoclax, azacitidine and mitoxantrone in acute myeloid leukemia (AML) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Composite remission rate after treatment. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinemitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500109764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109764.